Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Leukemia. 2013 Apr;27(4):977-80. doi: 10.1038/leu.2012.264. Epub 2012 Sep 11.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Indoles / pharmacology
  • Indoles / therapeutic use*
  • Male
  • Middle Aged
  • Mitogen-Activated Protein Kinase 14 / antagonists & inhibitors*
  • Myelodysplastic Syndromes / drug therapy*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Indoles
  • Protein Kinase Inhibitors
  • SCIO-469
  • Mitogen-Activated Protein Kinase 14